Nasdaq IPOs

Renalytix AI, which is commercializing AI-powered diagnostic tests for kidney disease, raised $74 million by offering 5.5 million ADS equivalents at $13.50, below the as-converted last close of its shares on London's AIM board (RENX). At pricing, the company commands a fully dilu

Deerfield Healthcare Technology Acquisitions, the third healthcare-focused blank check company formed by Deerfield Management and Robert Barasch, raised $125 million by offering 12.5 million units at $10. Each unit consists of one share of common stock and one-fifth of a warrant,

ALX Oncology, a Phase 1 immuno-oncology biotech developing CD47 checkpoint inhibitors, raised $162 million by offering 8.5 million shares at $19, above the range of $15 to $17. The company offered 0.5 million more shares than anticipated. At pricing, the company commands a fully

Berkeley Lights, which provides a single cell manipulation platform for drug discovery and development, raised $178 million by offering 8.1 million shares at $22, above the upwardly revised range of $19 to $20. The company offered 0.7 million more shares than anticipated. It orig

Pandion Therapeutics, a Phase 1 biotech developing engineered T cells for autoimmune diseases, raised $135 million by offering a further upsized 7.5 million shares at $18, the high end of the $16 to $18 range. The company originally filed to offer 5.5 million shares, before incre

Fathom Holdings, a cloud-based full-service real estate brokerage, announced terms for its IPO on Thursday. The Cary, NC-based company plans to raise $20 million by offering 2.5 million shares (8% insider) at a price range of $7 to $9. At the midpoint of the proposed range, Fatho

1847 Goedeker, which operates an e-commerce platform for appliances and home goods, lowered the proposed deal size for its upcoming IPO on Thursday. The Ballwin, MO-based company now plans to raise $10 million by offering 1 million shares at a price range of $9 to $11. The compan

Pandion Therapeutics, a Phase 1 biotech developing engineered Treg cells for autoimmune diseases, increased the proposed share offering for its upcoming IPO on Thursday. The Watertown, MA-based company now plans to raise $119 million by offering 7 million shares at a price range

Berkeley Lights, which provides a single cell manipulation platform for drug discovery and development, raised the proposed range for its upcoming IPO on Thursday. The Emeryville, CA-based company now plans to raise $144 million by offering 7.4 million shares at a price range of

Trean Insurance Group, a specialty casualty insurer in the US focused on workers' compensation, raised $161 million by offering 10.7 million shares (67% primary) at $15, the high end of the range of $13 to $15. At pricing, the company commands a market cap of $767 million. Trean

Relay Therapeutics, a Phase 1 biotech developing precision small molecule therapies for solid tumors, raised $400 million by offering 20 million shares at $20, above the upwardly revised range of $18 to $19. The company originally planned to offer 14.7 million shares at $16 to $1

HPX Corp., a blank check company targeting a business in Brazil, raised $220 million by offering 22 million units at $10. The SPAC had originally planned to raise $200 million. Each unit consists of one share and one-half of a warrant, exercisable at $11.50. Co-Chairman Bern

CC Neuberger Principal Holdings II, the second blank check company formed by CC Capital and Neuberger Berman, filed on Wednesday with the SEC to raise up to $600 million in an initial public offering. The New York, NY-based company plans to raise $600 million by offering 60 milli

Acutus Medical, which manufactures tools for catheter-based ablation procedures to treat arrhythmia, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering. The company's diverse product portfolio includes its foundational product, the AcQMap ima

Nelson Griggs, President of Nasdaq Stock Exchange, expects a strong summertime IPO Market

Summer 2020 has featured a red-hot US IPO market, and nCino (NCNO) added to the heat on Tuesday, soaring 195% on its debut. That is the biggest IPO pop for a US tech company since August 2000. Including foreign tech issuers, nCino places second, behind Baidu, which popped 354% on

BioVie, a Phase 2 biotech developing therapies for cirrhosis, submitted an amendment on Wednesday with the SEC. The blank filing indicates that the company plans to raise up to $18 million in an initial public offering. The company is currently listed on the OTCQB (BIVI) and last

Relay Therapeutics, a Phase 1 biotech developing precision small molecule therapies for solid tumors, raised the proposed deal size for its upcoming IPO on Wednesday. The Cambridge, MA-based company now plans to raise $370 million by offering 20 million shares at a price range of

Malacca Straits Acquisition, a blank check company targeting a business in Southeast Asia, raised $125 million by offering 12.5 million units at $10. Each unit consists of one share of common stock and one-half of a warrant, exercisable at $11.50. At pricing, the company com

D8 Holdings, a blank check company targeting a global consumer brand, raised $300 million by offering 30 million units at $10. The company offered 5 million more units than anticipated. Each unit consists of one share and one-half of a warrant, exercisable at $11.50. At pricing,